Highlights Erasca, Inc.

Equities

ERAS

US29479A1088

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-16 EDT			5-day change	1st Jan Change
1.85 ^USD	-2.12%		-5.61%	-13.15%

05-08	Erasca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-03	North American Morning Briefing : Powell Awaited -2-	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Erasca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Erasca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Erasca, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-27	CI
Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials	02-14	CI
North American Morning Briefing : Boeing Drags -2-	01-08	DJ
Erasca, Inc. Receives FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma	12-11	CI
Erasca, Inc. Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway	11-28	CI
Erasca, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Erasca, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Erasca Says US FDA Grants Orphan Drug Designation for ERAS-801 for Malignant Glioma	23-06-22	MT
Erasca, Inc. Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline	23-06-05	CI
Erasca, Inc. Announces Promising Preliminary Data for ERAS-007 Combinations in Patients with Gastrointestinal Malignancies as Part of Two Poster Presentations That Will Be Presented At the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois	23-05-25	CI
Erasca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Erasca, Inc. Receives Fda Fast Track Designation for Cns-Penetrant Egfr Inhibitor Eras-801 in Patients with Glioblastoma	23-05-01	CI
Erasca, Inc. Presents Initial Phase 1B Dose Escalation Data from Flagshp-1 for Eras-601 Plus Cetuximab in Patients with Advanced Solid Tumors At the 2023 AACR Annual Meeting	23-04-18	CI
ERASCA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-23	AQ
Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates	23-03-23	GL
Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates	23-03-23	GL
Erasca Gets FDA Clearance for ERAS-3490 Cancer Therapy Trial	22-12-13	MT
Erasca, Inc. Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors	22-12-13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Erasca, Inc.

Equities

ERAS

US29479A1088

Highlights

Filters